Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.
Yasuhiko MatsumoriMiki IshidaKatsuhiro IbaByung-Kun KimXiaoping NingMasami NakaiNobuyuki KogaPublished in: Headache (2023)
Patients with EM/CM receiving monthly or quarterly fremanezumab, for a duration of 12 weeks, showed significant improvements in their QoL.